Century Therapeutics Proposes Reverse Stock Split to Avoid Nasdaq Delisting

TL;DR

**IPSC is doing a reverse split to stay listed on Nasdaq; it's a desperate move to prop up the stock price, but it won't fix the underlying business.**

AI Summary

Century Therapeutics, Inc. (IPSC) is seeking stockholder approval for a reverse stock split of its common stock, with a ratio between 1-for-5 and 1-for-30, at a Special Meeting on January 22, 2026. The primary motivation for this action, unanimously approved by the Board on November 18, 2025, is to increase the per-share market price to meet Nasdaq's minimum $1.00 bid price requirement (Nasdaq Listing Rule 5450(a)(1)) and avoid delisting. Century received a deficiency letter on February 26, 2025, and failed to regain compliance by the Initial Compliance Date of August 26, 2025, necessitating an extension until February 23, 2026. The reverse split will not alter the number of authorized shares or relative voting power but will adjust outstanding stock options, restricted stock units, and warrants. As of November 15, 2025, 87,313,356 shares of common stock were outstanding. Major beneficial owners include Bayer World Investments B.V. with 14.52% and Versant Entities with 13.93%.

Why It Matters

This reverse stock split is a critical move for Century Therapeutics to maintain its Nasdaq listing, which is vital for liquidity and investor confidence. Delisting could severely impact the company's ability to raise capital and attract new investors, potentially hindering its drug development efforts in a highly competitive biotech landscape. For existing investors, while the split doesn't change their total ownership value, it signals underlying concerns about the stock's low trading price and the company's market perception. Employees and customers might view this as a sign of financial instability, though the company aims to improve its investment profile.

Risk Assessment

Risk Level: high — The company explicitly states, "There are certain risks associated with a reverse stock split, and we cannot accurately predict or assure the Reverse Stock Split will produce or maintain the desired results." The primary reason for the split is to avoid delisting from Nasdaq due to failing the $1.00 minimum bid price requirement, indicating significant stock underperformance and potential investor skepticism.

Analyst Insight

Investors should carefully consider the underlying reasons for the low stock price and the company's long-term prospects, rather than just the cosmetic change of a reverse split. Evaluate the company's pipeline, cash burn, and competitive position. This move often signals distress, so proceed with caution and consider reducing exposure if fundamental improvements aren't evident.

Key Numbers

• $1.00 — Nasdaq minimum bid price requirement (Century Therapeutics failed to meet this requirement, leading to the proposed reverse stock split.)
• 1-for-5 and 1-for-30 — Reverse stock split ratio range (The Board has discretion to choose any whole number ratio within this range.)
• February 26, 2025 — Date of Nasdaq deficiency letter (Century Therapeutics was notified of non-compliance with the minimum bid price rule.)
• August 26, 2025 — Initial Compliance Date (Century Therapeutics did not regain compliance by this date.)
• February 23, 2026 — Extended Compliance Date (New deadline for Century Therapeutics to regain Nasdaq compliance.)
• 87,313,356 — Shares of Common Stock outstanding (As of November 15, 2025, before any reverse stock split.)
• 14.52% — Beneficial ownership by Bayer World Investments B.V. (Largest beneficial owner of Century Therapeutics common stock.)
• 13.93% — Beneficial ownership by Versant Entities (Second largest beneficial owner of Century Therapeutics common stock.)
• 9:00 a.m., Eastern Time — Special Meeting time (The virtual Special Meeting will be held at this time on January 22, 2026.)
• November 18, 2025 — Date Board approved reverse stock split (The Board unanimously approved the proposal to seek stockholder approval.)

Key Players & Entities

• Century Therapeutics, Inc. (company) — Registrant seeking reverse stock split approval
• Nasdaq Capital Market (regulator) — Exchange where IPSC is listed, with a $1.00 minimum bid price requirement
• Brent Pfeiffenberger, Pharm.D. (person) — President, CEO & Chairman of the Board of Century Therapeutics
• Douglas Carr (person) — Senior Vice President, Finance and Operations, Principal Financial Officer and Secretary of Century Therapeutics
• Bayer World Investments B.V. (company) — Beneficial owner of 14.52% of Century Therapeutics common stock
• Versant Entities (company) — Beneficial owner of 13.93% of Century Therapeutics common stock
• FUJIFILM Cellular Dynamics, Inc. (company) — Beneficial owner of 7.97% of Century Therapeutics common stock
• Nasdaq Listing Qualifications Staff (regulator) — Issued deficiency letter to Century Therapeutics on February 26, 2025
• November 25, 2025 (date) — Record Date for stockholders entitled to vote at the Special Meeting
• January 22, 2026 (date) — Date of the Special Meeting of Stockholders

FAQ

Risk Factors

• Failure to Meet Nasdaq Minimum Bid Price Requirement [high — regulatory]: Century Therapeutics received a deficiency letter from Nasdaq on February 26, 2025, for failing to maintain a minimum bid price of $1.00. The company failed to regain compliance by the initial deadline of August 26, 2025, and has an extended deadline of February 23, 2026. Failure to meet this requirement will result in delisting from the Nasdaq Capital Market.
• Reverse Stock Split Dilution Concerns [medium — market]: The proposed reverse stock split, with a ratio between 1-for-5 and 1-for-30, aims to increase the per-share price. However, this action may not be sufficient to maintain compliance with Nasdaq's listing rules and could lead to a decrease in trading volume or investor interest if the stock price does not stabilize above $1.00.
• Dependence on Board Discretion for Split Implementation [low — operational]: The Board of Directors has the discretion to determine the specific ratio (between 1-for-5 and 1-for-30) and the timing of the reverse stock split. This lack of pre-determined certainty could create uncertainty for investors regarding the immediate impact on share price and outstanding share count.

Industry Context

The biotechnology sector, particularly companies focused on early-stage therapeutics, often faces significant capital requirements and regulatory hurdles. Companies like Century Therapeutics are highly dependent on achieving clinical milestones and securing funding to advance their pipelines. The competitive landscape is intense, with many companies vying for investor attention and limited capital, making adherence to exchange listing requirements critical for maintaining visibility and access to public markets.

Regulatory Implications

The primary regulatory implication is compliance with Nasdaq's listing rules, specifically the minimum bid price requirement. Failure to meet this requirement by February 23, 2026, will lead to delisting, significantly impacting the company's ability to raise capital and its stock's liquidity. The reverse stock split is a direct measure to address this regulatory non-compliance.

What Investors Should Do

1. Vote FOR Proposal 1 (Reverse Stock Split)
2. Vote FOR Proposal 2 (Adjournment)
3. Review the proposed reverse stock split ratio range (1-for-5 to 1-for-30)
4. Ensure your vote is cast by January 21, 2026

Key Dates

• 2025-02-26: Nasdaq deficiency letter received — Indicates non-compliance with Nasdaq's minimum bid price rule, triggering a compliance period.
• 2025-08-26: Initial Compliance Date — Century Therapeutics failed to regain compliance with Nasdaq's minimum bid price rule by this date.
• 2025-11-18: Board of Directors approved reverse stock split proposal — Formal decision by the board to seek stockholder approval for the reverse stock split to address Nasdaq non-compliance.
• 2025-11-25: Record Date for Special Meeting — Establishes the set of stockholders eligible to vote at the Special Meeting.
• 2025-12-02: Proxy Statement made available — Informs stockholders about the Special Meeting agenda and provides materials for voting.
• 2026-01-22: Special Meeting of Stockholders — Date for stockholders to vote on the proposed reverse stock split and other business.
• 2026-02-23: Extended Compliance Date — Final deadline for Century Therapeutics to regain compliance with Nasdaq's minimum bid price rule.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (The primary proposal at the Special Meeting, intended to increase the per-share market price to meet Nasdaq listing requirements.)

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders about matters to be voted on at a shareholder meeting. (This document outlines the proposed reverse stock split and provides the rationale and details for stockholders to consider.)

Nasdaq Listing Rule 5450(a)(1)

A rule set by the Nasdaq stock exchange that requires listed companies to maintain a minimum bid price of $1.00 per share. (Century Therapeutics is currently non-compliant with this rule, necessitating the proposed reverse stock split.)

Common Stock

Represents ownership in a corporation and entitles the stockholder to voting rights and a share in the company's profits. (The shares of common stock are subject to the proposed reverse stock split.)

Charter

The foundational document of a corporation, outlining its basic structure, purpose, and powers. (An amendment to the Charter is required to implement the reverse stock split.)

Beneficial Owner

An individual or entity that has the ultimate power to direct the voting and/or investment of a security, even if the security is held in the name of a broker or nominee. (Important for understanding voting rights and how shares are represented at the Special Meeting, especially for those holding shares in 'street name'.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the critical proposal of a reverse stock split, driven by a specific regulatory concern (Nasdaq minimum bid price). Unlike typical annual filings that detail financial performance, revenue growth, and operational achievements over a fiscal year, this document's primary purpose is to address an immediate compliance issue. Therefore, direct comparisons of financial metrics like revenue, net income, or margins to a previous filing are not the focus here; instead, the emphasis is on the company's efforts to maintain its stock exchange listing.

Key Financial Figures

• $0.0001 — nding shares of common stock, par value $0.0001 per share ("Common Stock") by a ratio o
• $1.00 — ") by evidencing a closing bid price of $1.00 or more per share for a minimum of ten
• $1.00 m — ays, we were not in compliance with the $1.00 minimum bid price requirement for continu

Filing Documents

• tm2531763-4_def14a.htm (DEF 14A) — 277KB
• lg_centurytherapeutics-4clr.jpg (GRAPHIC) — 16KB
• ic_mailpho-4c.jpg (GRAPHIC) — 57KB
• px_25centuryproxy1pg01-bwlr.jpg (GRAPHIC) — 362KB
• px_25centuryproxy1pg02-bw.jpg (GRAPHIC) — 139KB
• 0001104659-25-117704.txt ( ) — 1018KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL The following table sets forth certain information regarding the beneficial ownership of Common Stock as of November 15, 2025, except to the extent otherwise indicated in the footnotes below, by (a) each person known by us to be the beneficial owner of more than 5% of the outstanding shares of Common Stock, (b) each named executive officer of the Company, (c) each director of the Company, and (d) all executive officers and directors as a group. The percentage of Common Stock outstanding is based on 87,313,356 shares of our Common Stock outstanding as of November 15, 2025. For purposes of the table below, and in accordance with the rules of the SEC, we deem shares of Common Stock subject to options that are currently exercisable or exercisable within sixty days of November 15, 2025 to be outstanding and to be beneficially owned by the person holding the options or warrants for the purpose of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. Except as otherwise noted, each of the persons or entities in this table has sole voting and investing power with respect to all of the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise noted below, the street address of each beneficial owner is c/o Century Therapeutics, Inc., 25 North 38th Street, 11th Floor, Philadelphia, PA 19104. NAME OF BENEFICIAL OWNER SHARES BENEFICIALLY OWNED NUMBER OF SHARES PERCENTAGE Greater than 5% Stockholders Versant Entities(1) 12,166,109 13.93% FUJIFILM Cellular Dynamics, Inc.(2) 6,955,207 7.97% Bayer World Investments B.V.(3) 12,675,838 14.52% Named Executive Officers and Directors Brent Pfeiffenberger, Pharm.D.(4) 983,179 1.13% Douglas Carr(5) 542,861 * Gregory Russotti, Ph.D.(6) 1,096,189 1.26

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL (3) Based solely upon information set forth in a Schedule 13G filed on February 11, 2022. Bayer World Investments B.V. is a subsidiary of Bayer AG and voting and investment decisions with respect to these shares are made by Bayer AG's Board of Management, which consists of Werner Baumann, Liam Condom, Serena Lin, Wolfgang Nickl, Stefan Oelrich, and Heiko Schipper. Each of Messrs. Baumann, Condon, Nickl, Oelrich, Schipper, and Ms. Lin disclaim beneficial ownership over the shares held by Bayer World Investments B.V. The address for Bayer World Investments B.V. is Bayer AG, Kaiser-Wilhelm-Allee 3, 51373 Leverkusen, Germany. (4) Consists of (i) 635,378 shares of common stock; (ii) 1,089 restricted stock units that vest within 60 days of November 15, 2025; and (iii) options to purchase 346,712 shares of our common stock that can be exercised within 60 days of November 15, 2025. (5) Consists of (i) 391,693 shares of common stock; (ii) 875 restricted stock units that vest within 60 days of November 15, 2025; and (iii) options to purchase 150,293 shares of our common stock that can be exercised within 60 days of November 15, 2025. (6) Consists of (i) 349,281 shares of common stock; (ii) 1,500 restricted stock units that vest within 60 days of November 15, 2025; and (iii) options to purchase 745,408 shares of our common stock that can be exercised within 60 days of November 15, 2025; and (iv) 92,773 shares of Common Stock held by the Gregory Russotti 2021 Family Trust. Christine Russotti and Mary Jane Laurer are trustees. (7) Consists of options to purchase 227,227 shares of our common stock that can be exercised within 60 days of November 15, 2025. (8) Consists of (i) 5,000 shares of common stock and (ii) options to purchase 127,744 shares of our common stock that can be exercised within 60 days of November 15, 2025. (9) Consists of options to purchase 127,744 shares of our common

View Full Filing

View this DEF 14A filing on SEC EDGAR